Investment Analysts’ Recent Ratings Changes for Prelude Therapeutics (PRLD)

Several analysts have recently updated their ratings and price targets for Prelude Therapeutics (NASDAQ: PRLD):

• 5/4/2026 – Prelude Therapeutics is now covered by D. Boral Capital. They set a “buy” rating and a $9.00 price target on the stock.
• 5/1/2026 – Prelude Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 4/28/2026 – Prelude Therapeutics was upgraded by Zacks Research to “hold”.
• 4/27/2026 – Prelude Therapeutics had its price target raised by HC Wainwright from $5.00 to $8.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Prelude Therapeutics

In other news, Director Orbimed Advisors Llc purchased 2,815,315 shares of the company’s stock in a transaction that occurred on Tuesday, April 21st. The shares were purchased at an average price of $4.44 per share, with a total value of $12,499,998.60. Following the purchase, the director directly owned 11,808,945 shares of the company’s stock, valued at approximately $52,431,715.80. This represents a 31.30% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David P. Bonita purchased 2,815,315 shares of the company’s stock in a transaction that occurred on Tuesday, April 21st. The shares were purchased at an average cost of $4.44 per share, for a total transaction of $12,499,998.60. Following the purchase, the director directly owned 11,808,945 shares in the company, valued at $52,431,715.80. This trade represents a 31.30% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 49.20% of the company’s stock.

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.